


rel-Zotatifin

Cat. No.:	HY-112163A		
CAS No.:	2098191-54-7		
Molecular Formula:	C ₂₈ H ₂₉ N ₃ O ₅		
Molecular Weight:	487.55		
Target:	Eukaryotic Initiation Factor (eIF); SARS-CoV; Apoptosis		
Pathway:	Cell Cycle/DNA Damage; Anti-infection; Apoptosis		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



Relative stereochemistry

BIOLOGICAL ACTIVITY

Description

rel-Zotatifin is the racemic isomer of Zotatifin, acts as an eIF4A inhibitor with activity less than Zotatifin. Zotatifin (eFT226) is a potent, selective, and well-tolerated eIF4A inhibitor. Zotatifin promotes eIF4A binding to specific mRNA sequences with recognition motifs in the 5'-UTRs (IC₅₀=2 nM) and interferes with the assembly of the eIF4F initiation complex^[1].

REFERENCES

- [1]. Peggy A. Thompson, et al. Preclinical Evaluation of eFT226, a Novel, Potent and Selective eIF4A Inhibitor with Anti-tumor Activity in B-cell Malignancies.
- [2]. Gordon DE, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 2020 Apr 30.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA